PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD 667.00
-31.00 (-4.44%)
At close: Mar 9, 2026
PharmaEssentia Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 15,635 | 9,735 | 5,106 | 2,882 | 656.51 | Upgrade
|
| Revenue Growth (YoY) | 60.61% | 90.67% | 77.15% | 339.00% | 17.81% | Upgrade
|
| Cost of Revenue | 1,684 | 1,177 | 610.54 | 812.29 | 378.86 | Upgrade
|
| Gross Profit | 13,950 | 8,558 | 4,495 | 2,070 | 277.65 | Upgrade
|
| Selling, General & Admin | 5,554 | 4,234 | 4,184 | 2,672 | 1,827 | Upgrade
|
| Research & Development | 3,468 | 2,588 | 2,224 | 1,426 | 1,273 | Upgrade
|
| Operating Expenses | 9,022 | 6,822 | 6,408 | 4,098 | 3,100 | Upgrade
|
| Operating Income | 4,928 | 1,736 | -1,913 | -2,028 | -2,822 | Upgrade
|
| Interest Expense | -25.53 | -22.19 | -46.69 | -18.53 | -9.97 | Upgrade
|
| Interest & Investment Income | 649 | 924.06 | 585.13 | 40.44 | 4.63 | Upgrade
|
| Earnings From Equity Investments | -4.46 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -571.29 | 376.38 | 375.7 | 122.36 | -1.85 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.02 | -18.74 | 12.33 | 42.15 | 4.09 | Upgrade
|
| EBT Excluding Unusual Items | 4,985 | 2,996 | -986.93 | -1,842 | -2,826 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.03 | -0.93 | - | -0.1 | -0.07 | Upgrade
|
| Other Unusual Items | - | - | - | - | 14.59 | Upgrade
|
| Pretax Income | 4,983 | 2,995 | -986.93 | -1,842 | -2,811 | Upgrade
|
| Income Tax Expense | -62.23 | 29.15 | -363.1 | -467.06 | - | Upgrade
|
| Net Income | 5,045 | 2,966 | -623.84 | -1,375 | -2,811 | Upgrade
|
| Net Income to Common | 5,045 | 2,966 | -623.84 | -1,375 | -2,811 | Upgrade
|
| Net Income Growth | 70.13% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 370 | 368 | 358 | 315 | 289 | Upgrade
|
| Shares Outstanding (Diluted) | 371 | 371 | 358 | 315 | 289 | Upgrade
|
| Shares Change (YoY) | 0.13% | 3.58% | 13.47% | 9.24% | 7.39% | Upgrade
|
| EPS (Basic) | 13.64 | 8.06 | -1.74 | -4.36 | -9.74 | Upgrade
|
| EPS (Diluted) | 13.59 | 8.00 | -1.74 | -4.36 | -9.74 | Upgrade
|
| EPS Growth | 69.88% | - | - | - | - | Upgrade
|
| Free Cash Flow | 3,366 | 1,663 | -1,996 | -1,818 | -2,532 | Upgrade
|
| Free Cash Flow Per Share | 9.07 | 4.49 | -5.58 | -5.76 | -8.77 | Upgrade
|
| Dividend Per Share | 1.100 | 0.991 | - | - | - | Upgrade
|
| Dividend Growth | 10.98% | - | - | - | - | Upgrade
|
| Gross Margin | 89.23% | 87.91% | 88.04% | 71.82% | 42.29% | Upgrade
|
| Operating Margin | 31.52% | 17.83% | -37.48% | -70.37% | -429.91% | Upgrade
|
| Profit Margin | 32.27% | 30.46% | -12.22% | -47.70% | -428.17% | Upgrade
|
| Free Cash Flow Margin | 21.53% | 17.08% | -39.09% | -63.06% | -385.74% | Upgrade
|
| EBITDA | 5,061 | 1,847 | -1,824 | -1,912 | -2,703 | Upgrade
|
| EBITDA Margin | 32.37% | 18.97% | -35.73% | -66.34% | - | Upgrade
|
| D&A For EBITDA | 133.15 | 110.52 | 89.24 | 116.28 | 119.59 | Upgrade
|
| EBIT | 4,928 | 1,736 | -1,913 | -2,028 | -2,822 | Upgrade
|
| EBIT Margin | 31.52% | 17.83% | -37.48% | -70.37% | - | Upgrade
|
| Effective Tax Rate | - | 0.97% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.